They come from different places and are reported to act on different parts of repair. BPC-157 is a fragment of a protein found in gastric juice, associated with angiogenesis and growth-factor signalling. TB-500 reproduces the actin-binding region of thymosin beta-4, associated with cell migration. That complementarity is why they are so often studied together rather than against each other.
| BPC-157 from $75 | TB-500 from $80 | |
|---|---|---|
| Origin | Gastric juice protein fragment | Thymosin beta-4 fragment |
| Length | 15 amino acids | 7 amino acids (active region) |
| Reported mechanism | Angiogenesis, VEGF, nitric oxide | G-actin binding, cell migration |
| Research focus | Tendon, ligament, gut lining | Wound, cardiac, corneal, muscle |
| Human trial data | Very little | On the parent protein, not the fragment |
| WADA status | Prohibited (S0) | Prohibited (S2) |
| Strengths stocked | 10MG, 20MG | 10MG |
Comparing these two as rivals misses the point of most of the literature: they turn up together far more often than they turn up in opposition. Tissue repair needs cells to arrive at a damaged site and needs blood supply to rebuild it, and the two compounds are associated with different halves of that.
Where they genuinely differ is provenance and evidence. BPC-157 has a large rodent literature concentrated among a small number of research groups. TB-500's parent protein, thymosin beta-4, has been through early human trials of its own — but TB-500 is a fragment, and research on the full protein does not automatically transfer to it.
TB-500 binds G-actin, the monomer form of actin. Cell migration depends on continuous assembly and disassembly of the actin cytoskeleton, so a regulator of that pool is a plausible lever on how quickly cells reach a site of damage.
BPC-157 has no established receptor. What the published animal work reports instead is increased VEGF receptor 2 expression and effects on nitric-oxide signalling — an angiogenic story rather than a cytoskeletal one. The absence of a named target is the fairest criticism of that literature.
The Wolverine Stack is both in one vial, and the reasoning is mechanistic rather than trial-based: there is no published study of the combination that establishes it outperforms either alone. What the blend does change is practical — one reconstitution, one ratio, one tested batch.
BPC-157 is a 15-residue stretch of body protection compound, a protein isolated from human gastric juice. The parent was identified in work on gastric protection, and the fragment was synthesised because it appeared to carry the activity without the rest of the molecule. Its defining practical property is stability: it survives in gastric acid where most peptides of its size do not, which is why so much of the animal literature uses oral administration.
TB-500 is the actin-binding region of thymosin beta-4, one of the most abundant proteins in many human cell types and present in wound fluid and platelets. Reproducing the active region rather than the 43-residue protein makes it cheaper and more practical to synthesise. The names are used interchangeably in marketing and should not be: a fragment and a full-length protein are different molecules, and research on one does not transfer automatically to the other.
BPC-157 has the larger volume of publications by far — hundreds of rodent studies covering tendon-to-bone healing, ligament injury, muscle crush models, gastrointestinal lesions and inflammatory bowel models. The weakness is concentration: a large share comes from a small number of related research groups, and registered human trials are very few and very small. Volume is not the same as independent corroboration, and anyone citing the count should know how it is distributed.
Thymosin beta-4 has a different shape of evidence: fewer papers, but including early-phase human trials in dry eye and epidermolysis bullosa, and cardiac repair work after infarction. TB-500 as a fragment appears mostly in preclinical work and in veterinary use, particularly in racehorses — which is where its anti-doping history comes from.
Neither compound has what would ordinarily be called a clinical evidence base. Both are worth studying; neither is established.
Both are short peptides and both are straightforward syntheses, so a genuine batch of either should test very clean — meaningfully below 99% by HPLC deserves a question rather than an explanation. Because they are cheap to make, the commercial risk is not sophisticated adulteration but carelessness: light fills, untested material, and mislabelling between the two.
BPC-157 is among the most counterfeited peptides sold online, for the simple reason that demand is high and buyers cannot test what arrives. Identity confirmation by mass spectrometry is the check that matters, and it is the one most suppliers do not publish.
Both ship lyophilised and both should be kept cold, dry and dark until reconstituted. The arithmetic is the same for each: a 10mg vial holds 10,000mcg however much bacteriostatic water is added.
No published work establishes a receptor for BPC-157. Mechanisms are inferred from downstream observations — VEGF receptor 2 expression, nitric-oxide signalling — rather than from a binding target, and that gap is the fairest criticism of the field.
For TB-500, the open question is how much of the thymosin beta-4 literature applies to a fragment of it. Actin binding is well characterised for the protein; the fragment is assumed to carry it.
Neither compound has human efficacy data of the kind that would support a claim about repair in people, and nothing on this page should be read as one.
BPC-157 is listed by name under WADA S0, the category for substances with no current approval for human therapeutic use anywhere. TB-500 falls under S2, alongside other growth factors affecting muscle, tendon or ligament repair and vascularisation. Both are prohibited at all times, in and out of competition, and both are specifically screened for.
The distinction between S0 and S2 is about why they are prohibited rather than how strictly. For an athlete subject to anti-doping rules the practical answer is identical for both compounds, including at club level in many sports.
BPC-157 is described in the literature as stable in human gastric juice, which is an odd property for a peptide and the reason the oral research route exists at all. Most peptides are destroyed by digestion, which is why injection is the default. The parent protein BPC is a gastric protein, so the fragment inheriting some resistance to that environment is at least mechanistically coherent.
TB-500 has no comparable property. It is a short linear peptide with ordinary clearance, and the research on it is parenteral throughout.
For storage both behave like typical lyophilised peptides: stable for long periods dry and cold, considerably shorter once reconstituted and refrigerated. Neither should be left at room temperature in solution, and neither benefits from being frozen after mixing.
Neither is registered in Australia, and neither can be legally supplied for human use here. Both are sold as research materials, to buyers aged 18 and over, for in-vitro and laboratory work.
That status is exactly why the certificate matters. There is no regulator checking what is in the vial, so the only evidence is the batch testing — identity by mass spectrometry, purity by HPLC, and a heavy-metals screen. We make both in Blacktown, NSW, and every batch is tested at ≥99% purity with 0 ppm heavy metals before it ships.
Both are commonly imported, and imported peptides carry a longer chain between synthesis and vial. Buying from an Australian lab shortens that chain and removes the customs risk, which is the practical argument rather than a patriotic one.
The literature describes it as stable there, which is unusual for a peptide and is why an oral research route exists for it. TB-500 has no comparable property.
No. Neither is registered in Australia, and both are sold strictly as research materials to buyers aged 18 and over.
BPC-157 has the larger preclinical literature, but nearly all of it is rodent work from a small number of groups. Neither has substantial human data.
No. The reported mechanisms differ: BPC-157 is associated with angiogenesis and growth-factor signalling, TB-500 with actin binding and cell migration.
No. Thymosin beta-4 is a 43-amino-acid protein; TB-500 reproduces its actin-binding region. The names are used interchangeably in marketing and should not be.
No. Its reported mechanisms are inferred from downstream observations such as VEGF receptor 2 expression, not from an identified binding target.
S0 covers substances with no current approval for human therapeutic use anywhere. S2 covers growth factors affecting muscle, tendon or ligament repair. Both are prohibited at all times.
Identity by mass spectrometry, purity by HPLC, and the fill weight. Both are simple, inexpensive syntheses, so a genuine batch should test very clean.
BPC-157 is a 15-amino-acid fragment of a gastric protein associated with angiogenesis. TB-500 is a shorter fragment of thymosin beta-4 associated with actin binding and cell migration.
They are frequently studied together, and we blend them as the Wolverine Stack. No published trial establishes that the combination beats either compound alone.
Neither has strong human evidence. BPC-157 has a large rodent literature from a narrow set of groups; thymosin beta-4 has early human trials, but TB-500 is a fragment of it rather than the same molecule.
Yes, both. BPC-157 is listed under WADA S0 and TB-500 under S2, prohibited at all times.
This comparison summarises published research for educational purposes. It is not medical advice. OzPeptides products are sold for research and laboratory use only, not for human consumption. 18+ only.